Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › letrozole

letrozole

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of letrozole

91 trials tracked of letrozole: 29 in phase 3 or 4 and 16 with published results. The most-cited published study has 767 citations.

91Trials tracked
29Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 4 7 Phase 3 22 Phase 2 47 Phase 1 5 Other / NA 10
  1. Phase 3 Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Completed · 767 cited
  2. Phase 3 Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy Completed · 646 cited
  3. Phase 3 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Completed · 551 cited
  4. Phase 3 Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Completed · 287 cited
  5. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 235 cited
  6. Phase 3 A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) Completed · 199 cited
Show 44 more trials
  1. Phase 3 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women Completed · 131 cited
  2. Phase 3 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Completed · 130 cited
  3. Phase 3 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Completed · 122 cited
  4. Phase 4 Combined Letrozole and Clomid in Women With Infertility and PCOS Completed · 97 cited
  5. Phase 3 A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] Completed · 76 cited
  6. Phase 3 Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer Completed · 38 cited
  7. Phase 3 Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Completed · 37 cited
  8. Phase 4 Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole Completed · 32 cited
  9. Phase 3 Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia Completed · 12 cited
  10. Phase 3 Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate Completed · 4 cited
  11. Phase 4 Pilot of Letrozole for Uterine Myomas Completed
  12. Phase 4 RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF Completed
  13. Phase 4 Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer Completed
  14. Phase 4 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer Completed
  15. Phase 4 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Completed
  16. Phase 3 Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer Completed
  17. Phase 3 The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer Completed
  18. Phase 3 Pregnancy in Polycystic Ovary Syndrome II Completed
  19. Phase 3 Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. Completed
  20. Phase 3 Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer Completed
  21. Phase 3 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed
  22. Phase 3 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer Completed
  23. Phase 3 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer Completed
  24. Phase 2 TRial on the Endocrine Activity of Neoadjuvant Degarelix Completed
  25. Phase 2 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed
  26. Phase 2 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Completed
  27. Phase 2 Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer Completed
  28. Phase 2 Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms Completed
  29. Phase 2 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed
  30. Phase 2 Letrozole in Preventing Breast Cancer in Postmenopausal Women Completed
  31. Phase 2 Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI) Completed
  32. Phase 2 Protocol for Women at Increased Risk of Developing Breast Cancer Completed
  33. Phase 2 BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer Completed
  34. Phase 2 A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer Completed
  35. Phase 2 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis Completed
  36. Phase 2 Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer Completed
  37. Phase 2 Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer Completed
  38. Phase 2 Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer Completed
  39. Phase 2 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments Completed
  40. Phase 2 Letrozole for Lymphangioleiomyomatosis Completed
  41. Phase 2 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer Completed
  42. Phase 2 A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer Completed
  43. Phase 2 Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Completed
  44. Phase 2 Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ Completed

Showing the 50 most-cited and recently-updated of 91 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
KAT6B::KANSL1 fusion identified in uterine mesenchymal neoplasm with no recurrence at 8 months
Rheumatology Sys. Review
KAT6B::KANSL1 fusion identified in uterine mesenchymal neoplasm with no recurrence at 8 months A rare genetic fusion explains a woman's uterine growth
This case report describes a 47-year-old woman with a 7-year history of a presumed uterine fibroid who underwent laparoscopic myomectomy and…
A woman with a long-term uterine growth was found to have a rare genetic fusion, helping doctors understand her specific condition.
Frontiers Oct 14, 2026
Higher prepregnancy HOMA-IR quartiles associated with lower clinical pregnancy and live-birth rates in PCOS
OB/GYN & Women's Health RCT
Higher prepregnancy HOMA-IR quartiles associated with lower clinical pregnancy and live-birth rates in PCOS Insulin resistance levels impact pregnancy success for women with PCOS
This secondary analysis of a randomized trial involving 746 women with PCOS found that higher prepregnancy HOMA-IR quartiles were associated…
Higher levels of insulin resistance before pregnancy are linked to lower ovulation rates and lower live birth rates in women with PCOS.
Oct 3, 2026
AI plus celecoxib more than doubles odds of clinical response in ER-positive breast cancer
Oncology RCT
AI plus celecoxib more than doubles odds of clinical response in ER-positive breast cancer Adding celecoxib to hormone therapy improves early breast cancer response
This Phase III randomized trial of 269 postmenopausal women with ER-positive resectable breast cancer found that adding celecoxib to an arom…
A new trial shows that adding the drug celecoxib to standard hormone therapy can improve initial clinical responses in postmenopausal women …
medRxiv Jul 18, 2026
Evaluating ctDNA Dynamics as Prognostic Biomarkers in Advanced HR+ HER2- Breast Cancer
Oncology Phase III
Evaluating ctDNA Dynamics as Prognostic Biomarkers in Advanced HR+ HER2- Breast Cancer Ribociclib and Letrozole Show Promise for Advanced Breast Cancer
This Phase IIIb trial evaluates how circulating tumor DNA (ctDNA) dynamics influence progression-free survival for patients treated with rib…
New data suggests that tracking specific genetic markers in the blood may help predict how well patients with advanced breast cancer respond…
Jun 18, 2026
Letrozole protocol associated with higher live birth and lower adverse outcomes versus estrogen-progesterone in ovulation disorder FET
Psychiatry Cohort
Letrozole protocol associated with higher live birth and lower adverse outcomes versus estrogen-progesterone in ovulation disorder FET Letrozole Prep Boosts Live Births, Lowers Risks
This single-center retrospective cohort study compared ovulation induction using Letrozole against an artificial programmed protocol using e…
Women with ovulation issues who take Letrozole before frozen embryo transfers have higher live birth rates and lower risks of miscarriage an…
Frontiers Apr 13, 2026
Letrozole reduces Ki67 in postmenopausal ER+/HER2- breast cancer after 7-30 days pre-surgery
OB/GYN & Women's Health Phase II
Letrozole reduces Ki67 in postmenopausal ER+/HER2- breast cancer after 7-30 days pre-surgery Can a short course of letrozole before surgery help shrink hormone-sensitive breast cancer?
A phase 2 trial of 61 postmenopausal women with ER+/HER2- operable breast cancer evaluated a 7- to 30-day preoperative course of letrozole 2…
Doctors can now get a real-time snapshot of how hormone-sensitive breast cancer responds to letrozole before surgery in postmenopausal women…
CT.gov Mar 30, 2026